A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

编者按：2026年欧洲肿瘤内科学会乳腺癌大会（ESMO BC）将于5月6日至8日在德国柏林举行，本届大会将覆盖乳腺癌的靶向治疗、内分泌治疗及免疫治疗等前沿领域，并公布多项重磅研究成果，亮点纷呈。近年来，中国乳腺癌领域进展迅速，本届大会中共有64项研究入选，凸显了中国研究的国际影响力。《肿瘤瞭望》特对大会中中国专家的口头报告（2项）和壁报（62项）题目进行汇总，以供读者参考，如有缺漏或错误，欢迎指正 ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 ...

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with residual invasive disease, with a regulatory decision anticipated in Q3 2026.

Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease after neoadjuvant ...

A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Roche Holdings AG RHHBY on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the ...

Enhertu, or famtrastuzumab deruxtecan-nxki, is an HER2 directed DXd antibody drug conjugate. It was discovered by Tokyo-based Daiichi, but is being co-developed and commercialised with Cambridge, ...